Full-Time

Principal Scientist

Analytical Development

Posted on 5/1/2024

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops small molecule protein degraders

Biotechnology

Senior

Belmont, MA, USA

Required Skills
Communications
Data Analysis
Requirements
  • PhD in Analytical Chemistry or related life sciences field preferred
  • 7+ years of experience in CMC analytical development
  • Strong problem-solving and troubleshooting skills
  • Demonstrated leadership, planning, and organizational skills
  • Excellent oral and written communication skills
  • Experience in developing impurity control strategies
  • In-depth expertise in test method development and qualification
  • Broad analytics expertise with techniques like HPLC, GC, MS, NMR, etc.
  • Knowledge of compendial testing methods (USP/EP)
  • Strong working knowledge of GLP, cGMP, and ICH requirements
  • Experience writing analytical sections in regulatory filings
  • Experience providing technical guidance to CDMOs and contract test labs
  • Experience working cross-functionally among project teams
Responsibilities
  • Develop method development platform for testing methods
  • Accountable for development and validation of critical test methodologies
  • Characterize drug substance and product-related impurities
  • Design and monitor ICH stability programs
  • Manage analytical development activities at CDMOs and contract labs
  • Implement and operate analytical capabilities in a new lab
  • Author CMC analytical sections in regulatory filings
  • Collaborate with internal and external stakeholders

Kymera Therapeutics, specializing in developing small molecule protein degraders for immunology-inflammation and oncology, utilizes their cutting-edge Pegasus platform to target and degrade disease-causing proteins effectively. This focus not only places them at the forefront of biomedical research within these critical health areas but also fosters a culture of technical excellence and leadership in medical innovation. An employment opportunity at this company promises a collegiate environment where scientific rigor is paired with a commitment to improving patient outcomes through pioneering therapies.

Company Stage

IPO

Total Funding

$879M

Headquarters

Watertown, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

10%

2 year growth

34%